News

Channel Medsystems® Receives U.S. FDA Approval of the Cerene® Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding

Emeryville, California, April 2, 2019. Channel Medsystems®, a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that the U.S. Food and Drug Administration (FDA) has approved the Cerene® Cryotherapy Device as a new approach to treating heavy menstrual bleeding. The Cerene Device delivers cryotherapy to freeze the lining of the […]

Channel Medsystems® Receives U.S. FDA Approval of the Cerene® Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding Read More »

Liberate Medical’s VentFree™ Muscle Stimulator Receives Breakthrough Device Designation from the FDA to Reduce Mechanical Ventilation Duration

Crestwood, KY, 24th January 2019 – Liberate Medical, a clinical stage medical device company, focused on the development of novel non-invasive neuromuscular electrical stimulation devices to address pulmonary conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s VentFree muscle stimulator. The proposed indication for the

Liberate Medical’s VentFree™ Muscle Stimulator Receives Breakthrough Device Designation from the FDA to Reduce Mechanical Ventilation Duration Read More »

Procyrion Named Most Innovative Heart Pump Technology in 2018 Global Healthcare and Pharmaceutical Awards

HOUSTON, TEXAS (August 23, 2018) – Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the

Procyrion Named Most Innovative Heart Pump Technology in 2018 Global Healthcare and Pharmaceutical Awards Read More »

Procyrion Selects Former Abbott/St. Jude Medical Group President Dr. Eric S. Fain as CEO

Houston, TX (July 23, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. The Board of Directors tapped Dr. Fain to build upon the foundation of innovative technology established over recent

Procyrion Selects Former Abbott/St. Jude Medical Group President Dr. Eric S. Fain as CEO Read More »

Medical Device Company Procyrion, Inc. Hires Three to Support Growth; Continues to Build Team

HOUSTON, TEXAS (July 10, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, announced today it has hired three additional team members to support the advancement of its intra-aortic heart pump, AortixTM, for use in NYHA Class III-IV heart failure patients. Patricia DaSilva, Margo Fendrich, and Aaron

Medical Device Company Procyrion, Inc. Hires Three to Support Growth; Continues to Build Team Read More »

Podimetrics honored as winner in the 2018 Medical Design Excellence Awards (MDEA)

Podimetrics today announced that the Podimetrics Remote Temperature Monitoring (RTM) System has been selected as the Bronze Winner in the Rehabilitation and Assistive Technology Products category of the 20th Annual Medical Design and Excellence Awards competition. The 2018 winning products were announced at the MDEA Ceremony held Tuesday, June 12, 2018 in conjunction with MD&M

Podimetrics honored as winner in the 2018 Medical Design Excellence Awards (MDEA) Read More »

Centese CEO, Evan Luxon Named Innovator of the Year

Pipeline Inc. held its annual entrepreneurial awards gala Thursday evening, which honored several local entrepreneurs and introduced the 2018 Pipeline class members.  Evan Luxon received Innovator of the Year, which is based on three components: performance during the Pipeline fellowship year; scores from the fellows’ retooled business plans post-Pipeline modules; and scores from the pitch

Centese CEO, Evan Luxon Named Innovator of the Year Read More »

Channel Medsystems® Secures $14.1mm Financing for Office-Based Treatment of Heavy Menstrual Bleeding

Emeryville, California, August 23, 2017. Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific. Channel Medsystems has developed

Channel Medsystems® Secures $14.1mm Financing for Office-Based Treatment of Heavy Menstrual Bleeding Read More »

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device

Emeryville, California, June 26, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device Read More »

Channel Medsystems® Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure

Emeryville, California, March 20, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the successful completion of the treatment phase in its CLARITY Pivotal Study. The goal of the CLARITY study is to evaluate the safety and effectiveness of the Cerene® Cryotherapy Device (Cerene device) in 242 women

Channel Medsystems® Completes Treatments in Largest Single-Arm Pivotal Study of Endometrial Ablation; Demonstrates Feasibility of Comfortable, Office-Based Procedure Read More »